Medical oncologists offer comprehensive insights on the role of circulating tumor DNA in the treatment of patients with colorectal cancer.
Lenvatinib/Pembrolizumab/TACE Regimen Improves PFS in Intermediate-Stage HCC
Josep M. Llovet, MD, PhD, discussed the updated data from the LEAP-012 trial in intermediate-stage hepatocellular carcinoma.
Read More
LaPelusa’s Journey in the Dynamic Field of GI Oncology
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
Listen
FDA Pushes Back Decision on Sotorasib/Panitumumab in Colorectal Cancer
The FDA was expected to decide on the application of sotorasib and panitumumab for the treatment of metastatic colorectal cancer on October 17, 2024.
Behind the FDA Approval of Fruquintinib for Previously Treated mCRC
In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.
Namodenoson Earns FDA Orphan Drug Designation in Pancreatic Cancer
The sponsor is preparing a phase 2 study to evaluate namodenoson in this patient population.
FDA Approves Cologuard Plus Stool DNA Test for Colorectal Cancer Screening
The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.